Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Exclusion Criteria

• •1. Subject with known hypersensitivity to methylnaltrexone, naltrexon or other opioids
• •2. Subject consuming any prescription medication within the past two weeks, over-the-counter (OTC) products within seven days, any experimental medication within 30 days prior to study screening, or of any drug with a half-life longer then three days within 10 half-lives (\>30 days) of screening
• •3. Subject consuming barbiturates or other inducers or inhibitors of CYP450 within 3 months of screening
• •4. Subject with history or evidence of cardiovascular, gastrointestinal, hepatic, neurological, pulmonary, and renal or other significant chronic illness.